FDA Approves LaserSight LSX for Myopic Astigmatism

WINTER PARK, Fla., Oct. 3 -- LaserSight Inc. said that the FDA has approved its LaserScan LSX precision microspot scanning excimer laser system for the LASIK treatment of myopia (nearsightedness) with and without astigmatism. The approval is for a range of treatment of refractive errors up to -6.00 diopters manifest refraction spherical equivalent (MRSE) with or without a refractive astigmatism up to 4.5 diopters of cylinder.

The range of spherical equivalent approved for treatment is reported to address approximately 85 percent of the myopic patients currently applying for refractive surgery. In November 1999, the Company's LaserScan LSX was approved for treatment by photorefractive keratectomy of nearsightedness up to -6.00 diopters; however refractive surgeons in the US are permitted to treat patients for nearsightedness up to -10.00 diopters.